Navigation Links
Mirati Therapeutics Reports Third Quarter 2013 Financial Results
Date:11/12/2013

SAN DIEGO, Nov. 12, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the third quarter and nine months ended September 30, 2013.

Recent Corporate Highlights

  • Completed financing that generated net proceeds of $53.0 million
  • Strengthened our world-class precision medicine team with addition of Isan Chen to the position of chief medical and development officer
  • Progressed new formulations for MGCD265 with a goal of initiating dose expansion cohorts in selected patient populations in the first quarter of 2014
  • Initiated development plans for mocetinostat in patients with myelodysplastic syndrome, with a dose confirmation study expected to begin this year and plans to finalize discussions and obtain a special protocol assessment from the FDA for the design of a Phase III trial in the first half of 2014
  • "This has been a year of great progress for Mirati, we completed a successful financing ($53.0 million), built out an extremely accomplished precision medicine team and restructured the corporation, which will allow us to aggressively advance our oncology pipeline," said Dr. Charles Baum, president and CEO of Mirati. "In 2014, we will use the foundation we have built to achieve key milestones in each of our programs. By mid-2014 we plan to have confirmation of clinical activity for MGCD265, our kinase inhibitor program targeting Met, Axl and VEGFR, in selected solid tumor patients with high unmet need and potential accelerated approval registration paths. We also plan to initiate a Phase 1 study with MGCD516, our second multi-target kinase inhibitor program focused on Trk, RET, DDR and EphRs, in cancer patients by mid-2014 and to enter further expansion studies in selected tumor types by the end
    '/>"/>

    SOURCE Mirati Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Mirati Therapeutics Prices Public Offering Of Common Stock
    2. Sorrento Therapeutics Adopts Stockholder Rights Plan
    3. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
    4. Shield Therapeutics Files Investigational New Drug Application for ST10 for the Treatment of Iron Deficiency in Chronic Kidney Disease
    5. Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
    6. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
    7. Echo Therapeutics Announces Third Quarter 2013 Financial Results
    8. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
    9. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
    10. PDL BioPharma Provides $70 Million in Financing to Durata Therapeutics
    11. PTC Therapeutics to Present at Credit Suisse Annual Health Care Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... GLASGOW, Scotland , July 24, 2014 Cancer ... will gain access to state-of-the-art cancer treatment closer to home ... next year. Varian Medical Systems (NYSE: ... and an order was placed in June for four TrueBeam™ ... TrueBeam systems, which offer fast and efficient radiotherapy and radiosurgery ...
    (Date:7/24/2014)... July 24, 2014 Second Quarter ... President and Chief Executive Officer effective September 2, 2014 ... $20.4 million , BioGlue ® revenues grew ... ® revenues grew 22 percent year-over-year to $1.1 ... 20 percent year-over-year to $1.7 million , Tissue ...
    (Date:7/24/2014)... Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: ... it has filed a detailed complaint with the ... (NYSE: AGN ) apparent attempts to ... price of Valeant,s common shares by continuing to ... despite Valeant,s public statements correcting this misinformation. A ...
    Breaking Medicine Technology:Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 2CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 4CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 5CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 6CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 7CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 8CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 9CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 10CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 11CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 12CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 13CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 14CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 15CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 16CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 17Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 2Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 3Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 4Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 5Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 6
    ... YORK, Feb. 15, 2012 Delcath Systems, Inc. (NASDAQ: ... ( Instituto Europeo di Oncologia – IEO) introduced ... a Feb. 15 press conference and discussed the status ... CHEMOSAT is a critical new treatment option for patients ...
    ... ERT (NASDAQ: ERT ) announced today that it ... year 2011 Monday, February 27, after the market closes. After ... 5:00 PM ET that day. For the conference ... United States or 1-412-858-4600 when calling internationally. There will be ...
    Cached Medicine Technology:Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology 2Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology 3Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology 4ERT to Report Fourth Quarter and Full Year 2011 Operating Results 2
    (Date:7/24/2014)... July 24, 2014 CarePoint Health ... in hematology and oncology, Dr. Hitendra Upadhyaya, has ... system welcomes Dr. Upadhyaya to the community. Hundreds ... Health Medical Group, a comprehensive network of top ... wide range of specialties. This latest acquisition represents ...
    (Date:7/24/2014)... Pools and beaches are the place to be on ... for small children, so Amica Insurance is sharing ... Centers for Disease Control and Prevention, children between the ages ... injuries and deaths. It’s important to know the best practices ... offering the following tips from the American Red Cross:, ...
    (Date:7/24/2014)... This year the Walk to End Alzheimer’s in ... Life, will be held on Saturday, September 20 in Denver ... Run at 7:50 am, the untimed 5k Run at 8 ... Walk to End Alzheimer’s unites the entire community in a ... this devastating disease, “stated Linda Mitchell, CEO and president of ...
    (Date:7/24/2014)... a foreign material like a medical device or surgical ... always responds. According to Northwestern University,s Guillermo Ameer, most ... affect the device,s function. , "You will always get ... of biomedical engineering in Northwestern,s McCormick School of Engineering ... Feinberg School of Medicine. "A problem with commonly used ...
    (Date:7/24/2014)... Researchers at Le Bonheur Children,s Hospital and the ... a clinical trial of a new drug shown to ... healthy adult volunteers intranasally infected with respiratory syncytial virus ... respiratory tract infections in young children in the United ... the labs of Infectious Disease Specialist John DeVincenzo, MD. ...
    Breaking Medicine News(10 mins):Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3Health News:Antioxidant biomaterial promotes healing 2Health News:RSV research breakthrough to help infected children 2
    ... 4 Nu Skin Enterprises, Inc. (NYSE: NUS ... quarterly dividend of $0.115 per share, which will be paid ... 15, 2009. , , The Company , ... its tradition of innovation through its comprehensive anti-aging product portfolio, ...
    ... planned benefit changes , , PORTLAND, Ore., June 4 ... perfect storm of rising health care costs and the declining ... three years of predictable rate adjustments and planned benefit changes, ... economic uncertainties. , , In these trying ...
    ... DIEGO, June 4 NuVasive, Inc. (Nasdaq: NUVA ... minimally disruptive surgical treatments for the spine, announced today that ... to present at the 8th Annual Needham Life Sciences Conference ... York, on Thursday, June 11, 2009, at 11:00 a.m. Eastern ...
    ... violent relationship may lead to poor mental health, ... --Adults who witnessed parental violence while growing up ... according to researchers who studied 3,023 adults in ... current depression, as well as their experiences with ...
    ... - , , - Total Net Sales in Line with Previous ... Today at 3:30 pm Central Time - , ... a medical device company that develops, manufactures and markets innovative proprietary products ... and full year ended March 31, 2009. Net sales of $2.9 ...
    ... is proud to announce the four finalists for its ... a competition to find Minnesota,s most innovative and effective ... cash awards as part of the Engaged Philanthropy Conference ... Graves 601 Hotel in Minneapolis. The Social Entrepreneur,s Cup ...
    Cached Medicine News:Health News:Regence Rate Assure(SM) Offers Employer Groups Guaranteed Rates, Benefits 2Health News:NuVasive to Present at the 8th Annual Needham Life Sciences Conference 2Health News:NuVasive to Present at the 8th Annual Needham Life Sciences Conference 3Health News:When Parents Fight, Children Often End Up With Scars 2Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 2Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 3Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 4Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 5Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 6Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 7Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 8Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 9Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 10Health News:Uroplasty Reports Fourth Quarter and Full Year Fiscal 2009 Results 11Health News:Social Entrepreneur's Cup Finalists Announced 2Health News:Social Entrepreneur's Cup Finalists Announced 3Health News:Social Entrepreneur's Cup Finalists Announced 4Health News:Social Entrepreneur's Cup Finalists Announced 5
    Collars can be attach to any Pulse aprons....
    This apron was designed by Pulse Medical-RCI for optimal protection. Your comfort is also a primary concern so a wide support belt and shoulder pads are standard. When properly fitted, an overlapping...
    ... necessary, the Two-Piece should be your ... comfort through more efficient distribution of ... vest comes with shoulder pads and ... well as an attached belt to ...
    Quick Release buckle apron is user friendly with large support straps crisscrossing the back allowing proper placement of the belt at your waist....
    Medicine Products: